Online inquiry

IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2963MR)

This product GTTS-WQ2963MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2963MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12270MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ14161MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ12877MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ4753MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ3190MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ7420MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ1478MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ4757MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BPS-804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW